Braille Institute Library to Host Livestream Event with Pulitzer Prize Finalist Andrew Leland on January 16, 2025
December 18, 2024 09:00 ET
|
Braille Institute
Braille Institute to host book talk with Pulitzer Prize finalist, Andrew Leland, author of The Country of the Blind: A Memoir at the End of Sight.
EyeDNA Therapeutics Receives Rare Pediatric Disease Designation from FDA for its Investigational Gene Therapy HORA-PDE6b for Patients with Retinal Dystrophy due to PDE6b Gene Mutations
December 17, 2024 06:00 ET
|
Coave Therapeutics
PDE6b-related Retinitis Pigmentosa is a rare inherited retinal dystrophy affecting up to 3,000 people in the US Symptoms often start in childhood leading to blindness by midlife with no approved...
Latest Published 5 Rare Eye Diseases Market Reports by DelveInsight: Retinitis Pigmentosa, Stargardt Disease, Ocular Melanoma, Uveitis, and Neurotrophic Keratitis
December 16, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Latest Published 5 Rare Eye Diseases Market Reports by DelveInsight: Retinitis Pigmentosa, Stargardt Disease, Ocular Melanoma, Uveitis, and...
Verana Health Introduces Qdata Explorer in Advance of 2024 American Academy of Ophthalmology Annual Meeting
October 09, 2024 09:00 ET
|
Verana Health, Inc.
SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Today, Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD),...
AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B
September 16, 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study
Retinitis Pigmentosa Clinical Trial Pipeline Insights Featuring 40+ Companies | DelveInsight
May 07, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 07, 2024 (GLOBE NEWSWIRE) -- Retinitis Pigmentosa Clinical Trial Pipeline Insights Featuring 40+ Companies | DelveInsight Retinitis pigmentosa is a genetic disorder characterized...
Retinitis Pigmentosa Market Size Expected to Reach USD 21.40 Bn by 2033
May 06, 2024 09:49 ET
|
Precedence Research
Ottawa, May 06, 2024 (GLOBE NEWSWIRE) -- The global retinitis pigmentosa market size was valued at USD 14.02 billion in 2023 and is predicted to hit around USD 19.90 billion by 2032, a study...
Nacuity Pharmaceuticals Announces Expansion of its Business Advisory Board with Appointment of Rare Disease Advocate Daniel Feller
February 14, 2024 09:00 ET
|
Nacuity Pharmaceuticals, Inc.
FORT WORTH, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other...
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
February 14, 2024 07:30 ET
|
Ocugen
Highlighting updates on OCU400 Phase 3 clinical trial starting early 2024 Featuring thought leaders in gene therapy and OCU400 Phase 1/2 clinical trial patient MALVERN, Pa., Feb. 14, 2024 ...
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
September 13, 2023 08:15 ET
|
Ocugen
Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects to dateClinical study update suggests continued positive trends in Best-Corrected Visual Acuity...